NBTX — Nanobiotix S.A.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1760854 ·
Last close
$27.45
Market Cap
$1.39B
52W High
$57.14
52W Low
$19.14
ADV30
143,108
Next earnings
2026-09-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 128,331,000 110,891,000 161,713,000
Dec 2025 — — — — 67,760,000 52,750,000 152,243,000
Jun 2025 — — — — 45,174,000 28,818,000 114,126,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-34,288,000
Inventory
—
Receivables
$9,369,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$32,593,000
EBITDA
$-10,489,000
Free Cash Flow
$-7,894,125
Enterprise Value
$1,833,406,976
Total Cash
$52,750,000
Total Debt
$95,319,000
Shares Out
50,811,344
Trailing EPS
$-0.58
Book Value
$-2.02
ROE
—
ROA
-10.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 29,643,000 -10,818,000 -23,961,000 67,760,000 152,243,000 -84,483,000 -33,422,000
Dec 2024 -11,610,000 -68,392,000 -68,132,000 67,418,000 133,121,000 -65,703,000 -19,551,000
Dec 2023 30,058,000 -26,778,000 -39,700,000 93,897,000 95,741,000 -1,844,000 -12,476,000
Dec 2022 0 -46,703,000 -57,041,000 59,769,000 86,814,000 -27,045,000 -37,103,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.34

Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $30.00 · spot: $26.90 · call volume: 1 · put volume: 100

Peers — same industry

TickerNameMarket CapLastDaily %
DMRA Damora Therapeutics, Inc. $1.40B $22.56 —
RAPP Rapport Therapeutics, Inc. $1.41B $23.76 —
NUVB Nuvation Bio Inc. $1.37B $3.90 —
ANAB ANAPTYSBIO, INC $1.36B $45.61 —
TYRA Tyra Biosciences, Inc. $1.35B $19.57 —

News headlines (Yahoo Finance, 1h cache)

Voting Rights and Shares Capital of the Company
2026-11-12 21:15 · Yahoo
Nanobiotix to Participate in Investor Conferences in November
2026-11-09 21:15 · Yahoo
Nanobiotix (ENXTPA:NANO) Could Be 46% Undervalued As Melanoma Trial Results Land
2026-10-26 23:31 · Yahoo
Nanobiotix stock gains on positive melanoma trial data
2026-10-26 15:35 · Yahoo
Nanobiotix (ENXTPA:NANO) Could Be 59% Undervalued After Its CFO Change
2026-10-10 17:11 · Yahoo
Can J&J’s Partnership Drive More Upside for Nanobiotix?
2026-09-28 19:31 · Yahoo
Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?
2026-09-17 17:06 · Yahoo
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
2026-10-24 11:00 · Yahoo
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
2026-10-01 20:15 · Yahoo
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
2026-09-24 20:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.